Journal Article
|Short ReportCulture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, Alam MS, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison CCH, Islam S, Khachatryan N, Kotrikadze T, Khan UT, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich ML, Wanjala S, Yedilbayev A, Huerga H, Mitnick CD, endTB Study Group
Abstract
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Countries
Subject Area
Languages
English